Ketamine in Pediatric Oncology: a drug review
- Satya Prakash,
- Aditya Gupta,
- J Meena
Abstract
Ketamine is a dissociative anesthetic agent, with excellent analgesic
properties and a favorable safety profile. Although it acts
predominantly through NMDA receptor antagonism, numerous other molecular
targets have been characterized, rendering anti-inflammatory,
anti-depressant, and thus expanding its scope for new clinical
applications. The noticeable safety of ketamine in children enables its
widespread use in pediatric oncology, chiefly for procedural sedation.
Its value for chronic pain management in children with cancer is being
increasingly recognized but requires more evidence. The topical use of
ketamine is largely in investigational stages.. Rational medical use of
ketamine is largely free from significant long-term neurological side
effects but may have some troublesome short-term effects such as
vomiting, palpitations, urinary retention, and hallucinations. This
review will provide a brief account of the pharmacology of ketamine and
primarily focus on the relevant aspects of ketamine in pediatric
oncology.25 Aug 2020Submitted to Pediatric Blood & Cancer 25 Aug 2020Submission Checks Completed
25 Aug 2020Assigned to Editor
31 Aug 2020Reviewer(s) Assigned
05 Sep 2020Review(s) Completed, Editorial Evaluation Pending
15 Sep 2020Editorial Decision: Revise Major
27 Sep 2020Submission Checks Completed
27 Sep 2020Assigned to Editor
27 Sep 20201st Revision Received
28 Sep 2020Reviewer(s) Assigned
29 Sep 2020Review(s) Completed, Editorial Evaluation Pending
13 Oct 2020Editorial Decision: Revise Minor
16 Oct 2020Submission Checks Completed
16 Oct 2020Assigned to Editor
16 Oct 20202nd Revision Received
19 Oct 2020Review(s) Completed, Editorial Evaluation Pending
19 Oct 2020Editorial Decision: Accept